8 results about "Wnt antagonists" patented technology

To provide a defined culture medium for isolating stratified epithelial stem cells and stably maintaining the epigenetics of the stratified epithelial stem cells during multiple passages, and to provide clonal stratified epithelial stem cells isolated using the defined culture medium.SOLUTION: And a defined culture medium comprising each of ROCK (Rho kinase) inhibitors, mitogenic growth factors, insulin or IGF, TrkA inhibitors, and Oct4 activators, and comprising at least one of VEGF inhibitors, tyrosine kinase inhibitors, and / or FGF10 or FGF10 agonists, and optionally further comprising TGF β signaling pathway inhibitors and / or bone morphogenetic proteins (BMP) antagonists, wherein the defined culture medium supports epigenetically stable growth and proliferation of stem cells of stratified epithelial tissue origin in culture.SELECTED DRAWING: Figure 1

The invention discloses an IL-11 long-acting protein antagonist compound and application thereof, according to the sequence characteristics (SEQ ID NO.1) and receptor binding characteristics of human IL11 mutein, Cys mutation is introduced at a specific site by using site-specific mutagenesis, and an activity maintenance mutant is screened by means of cell activity. By utilizing a chemical reaction, fatty acids with different lengths of side chains C16-C22 are introduced into a Cys side chain for modification, and a long-acting product with kept activity is screened by virtue of cell activity again.

The invention relates to a nucleic acid aptamer for specifically recognizing fibroblast growth factor 10 (FGF10) protein as well as a screening method and application of the nucleic acid aptamer. The nucleic acid aptamer is at least one of FAS-1, FAS-4, FAS-9, FAS-10 and FAS-12, and is obtained by screening through a magnetic bead-SELEX (systematic evolution of ligands by exponential enrichment) technology. The aptamer can be combined with FGF10 protein with high affinity, the equilibrium dissociation constant (Kd) of the aptamer is within the range of 5-20 nM, and the aptamer has good recognition specificity. By means of the excellent performance, the nucleic acid aptamer has wide application prospects in construction of an efficient detection method of the FGF10 protein and research and development of an FGF10 antagonist.

The application discloses a genetically engineered probiotic preparation and its use in tumor immunotherapy. The genetically engineered probiotic contains an expression cassette regulated by an inflammation-responsive promoter, which can encode a novel trifunctional fusion protein. The fusion protein contains a secretion signal peptide, a human IL-1 receptor antagonist, a flexible linker, an anti-human GM-CSF nanobody, a second flexible linker, and an anti-human PD-L1 nanobody in sequence. In vitro experiments confirm that the fusion protein has complete biological activity, can simultaneously neutralize GM-CSF, block PD-1 / PD-L1 binding, and inhibit the IL-1 signaling pathway. Animal experiments show that oral administration of the probiotic can significantly enhance the anti-tumor efficacy of CAR-T cells, effectively prevent and alleviate cytokine release syndrome, and provide a safe and effective adjuvant therapy strategy for CAR-T therapy.

The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

This invention discloses the application of PACAP peptides as plant immunomodulators, belonging to the field of plant immunology technology. This invention is the first to apply PACAP to a plant system, discovering that it can act as a novel plant immunomodulator to regulate plant immune responses, thereby enhancing plant resistance to pathogenic microorganisms. Experimental results show that PACAP can rapidly induce intracellular calcium ion influx in Arabidopsis thaliana cells, activate the MAPK signaling pathway, and upregulate the expression of early immune marker genes such as FRK1. Furthermore, PACAP treatment significantly improves plant resistance to pathogens such as *Pseudomonas syringae* and *Ralstonia solanacearum*. This invention also confirms that not only does the full-length PACAP (1-38) possess plant immune-promoting activity, but its N-terminal truncated peptide (1-27) and receptor antagonist fragment (6-38) also have plant immune-inducing functions. This invention provides a new technical solution for the development of plant immune inducers.

The invention belongs to the technical field of microorganisms, and discloses an NTase protein, a screening method thereof and application of the NTase protein in preparation of an anti-phage signal system antagonist and / or an antibacterial preparation. The NTase protein provided by the invention specifically comprises an amino acid fragment with a sequence as shown in SEQ ID NO: 1 or a variant fragment with at least 70% sequence identity with the sequence as shown in SEQ ID NO: 1, the NTase protein has an excellent antagonistic effect on a CBASS system of prokaryotes, and the infection efficiency of viruses on prokaryotic cells can be improved by inhibiting the CBASS system; therefore, a better antibacterial effect is achieved, and the compound has a very excellent application prospect in research and development of novel antibacterial drugs.